Skinbiotherapeutics Share Discussion Threads

[manc10] 16/8/2018 11:20

there was a trade at 97500 it is a buy not a sell

[siennadelekat21] 16/8/2018 11:17

I guess the coming weeks will confirm Whether you're correct or not Mshilos: )

[riskybusiness1] 16/8/2018 11:17

Take advantage today of an overly cautious RNS. Biggest risk was the upscale which has been successful. Thank you for the cheaper shares.

[rafboy] 16/8/2018 10:58

Mshilos, if the trial were being delayed they would have had to say so in the RNS. They haven’t and they would certainly know by now if it was going to. I suggest you may be wrong this time around.

[manc10] 16/8/2018 10:48

you will probably go over to opti next to trash that nobody is bothered or interested what you say soh told the truth not a no mark like you

[mshilos] 16/8/2018 10:40

What do I know ?? Seeing as you asked, I work for a biotech company, as a patent expert. This will delay the trials by another 8-12 weeks minimum DYOR

[primal123] 16/8/2018 10:37

Link for what?

[montynj] 16/8/2018 10:35

Hence today's fall is classic case of derampers misleading other investors. The bull case is firmly intact

[montynj] 16/8/2018 10:33

Comment from elrico on his google bb:Further comment from SOH after I suggested the great news on manufaturing scale up was killed by what investors perceived as bad news (24/hr shelf life and further work) appeared to suggest this was a concern, only mitigated by the ability to freeze dry. Also comment on OPTI."The SBTX RNS is a very positive RNS . Manufacturing scale up was the biggest risk and this has been achieved with a partner!!. Also the ability to freeze dry is a major step forward as that gives you extended shelf life for the SkinBiotix technology which is key for partners looking to incorporate this sort of ingredient into products.  Product stability is typically a matter of formulation once your lysate is stable.  The RNS doesn't say the cream is not stable for longer than 24 hours.  Its says they have tested it for 24 hours and they are now testing for longer in preparation for the studies.  This is all part of the development process and they are updating investors as to this process."OPTI"My view remains more balanced in that Opti has had a good run and is in a strong position with a good pipeline of deal flow, new sales channels, some big opportunities in retail and pharma that we need to conclude successfully, and a strategy which will return dividends to shareholders at the right opportunity.  Summer is always slow and volatile as volumes tail off but we are developing a lot of opportunities which will hopefully come to fruition and be announceable in the coming days, weeks, or months."

[manc10] 16/8/2018 10:33

mishilos what do you know you have only done 3 posts all negative about sbtx let the scientists do there job not the speculators filtered

[danatkins] 16/8/2018 10:32

Primal do you have the link

[mshilos] 16/8/2018 10:27

I feel it would be very risky to invest more in this, as this will delay the trial and so the share price will fall even lower, until there is an RNS update on the formulation stability. It will go below 17 p for sure, at the initial IPO price launch . IMO. DYOR.

[primal123] 16/8/2018 10:13

Agree JJ, wasn't that long ago he was pumping Opti and SBTX and now posting negative things trying to get people to sell. Also I am sure he was pumping bitcoin too!

[matt123d] 16/8/2018 10:06

Technically not as appealing now, going to need some time.

[rafboy] 16/8/2018 10:02

This makes a massive difference. SOH has spelt it out and it is all fine IMHO. Thanks Primal for sharing.

[primal123] 16/8/2018 09:59

From SOH this morning. People need to stop speculating rubbish! SOH: The SBTX RNS is a very positive RNS . Manufacturing scale up was the biggest risk and this has been achieved with a partner!!. Also the ability to freeze dry is a major step forward as that gives you extended shelf life for the SkinBiotix technology. The RNS doesn't say the cream is not stable for longer than 24 hours. Its says they have tested it for 24 hours and they are now testing for longer in preparation for the studies. This is all part of the development process and they are updating investors as to this process.

[mshilos] 16/8/2018 09:54

This is going to fall baxk to the original IPO share price launch of 16.25 p as of April 7th 2017...or lower. Terrible situation...clinical trial wuill have to be delayed. DYOR.

[mshilos] 16/8/2018 09:53

This is going to fall baxk to the original IPO share price launch of 16.25 p as of April 7th 2017...or lower. Terrible situation...clinical trial wuill have to be delayed. DYOR.

[judijudi] 16/8/2018 09:38

someuwin is most certainly not one to be trusted
In my humble opinion

[jamjason] 16/8/2018 09:36

Someuwin, yes I thought the same too. Are you still holding here?

[someuwin] 16/8/2018 09:31

"SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester."

Now look at the last two holdings RNSs. In the last few weeks both Andrew McBain and University of Manchester have both reduced their holdings.

Form your own conclusions.

[fredd] 16/8/2018 09:28

Remains to be seen if there is a stability issue. It sounds to me as if they have to assess the stability of the successfully freeze dried compound in the cream formulation. Which is what one would expect. Happy to wait and see.
FD

[jamjason] 16/8/2018 09:19

I agree, the trial will more than likely be delayed now as I don't see how they can fix the stability issue in just a few weeks.

[rayrac] 16/8/2018 09:16

And then it has to work as a product! So how can they test it if they haven’t even got a stable, in the jar, product? That soh has something to answer for?

[rafboy] 16/8/2018 09:14

Whilst the cream may be the favoured delivery mechanism if the liquid works and is stable they could go with that first.